Altered responses of dopamine D3 receptor null mice to excitotoxic or anxiogenic stimuli: Possible involvement of the endocannabinoid and endovanilloid systems

Neurobiology of Disease

Volumn 36, Issue 1, 2009, Pages 70-80

  Micale, Vincenzo ^a   Cristino, Luigia ^b   Tamburella, Alessandra ^a   Petrosino, Stefania ^b   Leggio, Gian Marco ^a   Drago, Filippo ^a   Di Marzo, Vincenzo ^b  

^a UNIVERSITY OF CATANIA   (Italy)

^b CNR   (Italy)

Author keywords

Anxiety; D3 receptors; Dopamine; Endocannabinoid; Endovanilloid; Epilepsy; Knock out mice

Indexed keywords

CANNABINOID 1 RECEPTOR; DIAZEPAM; DOPAMINE 3 RECEPTOR; ENDOCANNABINOID; PICROTOXIN; VANILLOID RECEPTOR 1;

AMYGDALOID NUCLEUS; ANALYTIC METHOD; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICONVULSANT ACTIVITY; ANXIETY; ARTICLE; CLONIC SEIZURE; CONTROLLED STUDY; CORPUS STRIATUM; DENSITOMETRY; EPILEPSY; EXCITOTOXICITY; HIPPOCAMPUS; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; MALE; MAZE TEST; MORTALITY; MOUSE; NEUROPROTECTION; NONHUMAN; NUCLEUS ACCUMBENS; PRIORITY JOURNAL; STIMULUS RESPONSE; SURVIVAL TIME; WILD TYPE;

ANALYSIS OF VARIANCE; ANIMALS; ANTI-ANXIETY AGENTS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANXIETY; ARACHIDONIC ACIDS; BRAIN; CAPSAICIN; DIAZEPAM; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOCANNABINOIDS; EPILEPSY; GABA ANTAGONISTS; MALE; MAZE LEARNING; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; PICROTOXIN; PIPERIDINES; PYRAZOLES; REACTION TIME; RECEPTOR, CANNABINOID, CB1; RECEPTORS, DOPAMINE D3; SEROTONIN; TRPV CATION CHANNELS;

EID: 69749094153     PISSN: 09699961     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nbd.2009.06.015     Document Type: Article

References (61)

1. Accili D., Fishburn C.S., Drago J., Steiner H., Lachowicz J.E., Park B.H., Gauda E.B., Lee E.J., Cool M.H., Sibley D.R., Gerfen C.R., Westphal H., and Fuchs S. A targeted mutation of the D3 dopamine receptor gene is associated with hyperactivity in mice. Proc. Nat. Ac. Sci. USA 93 (1996) 1945-1949
2. Ahluwalia J., Urban L., Bevan S., and Nagy I. Anandamide regulates neuropeptide release from capsaicin-sensitive primary sensory neurons by activating both the cannabinoid 1 receptor and the vanilloid receptor 1 in vitro. Eur. J. Neurosci. 17 (2003) 2611-2618
3. Aroniadou-Anderjaska V., Fritsch B., Qashu F., and Braga M.F. Pathology and pathophysiology of the amygdala in epileptogenesis and epilepsy. Epilepsy Res. 78 (2008) 102-116
4. Bisogno T., and Di Marzo V. Short- and long-term plasticity of the endocannabinoid system in neuropsychiatric and neurological disorders. Pharmacol. Res. 56 (2007) 428-442
5. Bisogno T., Melck D., De Petrocellis L., Bobrov M., Gretskaya N.M., Bezuglov V.V., Sitachitta N., Gerwick W.H., and Di Marzo V. Arachidonoylserotonin and other novel inhibitors of fatty acid amide hydrolase. Biochem. Biophys. Res Commun. 248 (1998) 515-522
6. Buznego M.T., and Pérez-Saad H. Acute effect of an extract of Ambrosia paniculata (Willd.) O. E. Schultz (mugwort) in several models of experimental epilepsy. Epilepsy Behav. 5 (2004) 847-851
7. Chen G., Kittler J.T., Moss S.J., and Yan Z. Dopamine D3 receptors regulate GABAA receptor function through a phospho-dependent endocytosis mechanism in nucleus accumbens. J. Neurosci. 26 (2006) 2513-2521
8. Cristino L., De Petrocellis L., Pryce G., Baker D., Guglielmotti V., and Di Marzo V. Immunohistochemical localization of cannabinoid type 1 and vanilloid transient receptor potential vanilloid type 1 receptors in the mouse brain. Neuroscience 139 (2006) 1405-1415
9. de Lago E., de Miguel R., Lastres-Becker I., Ramos J.A., and Fernández-Ruiz J. Involvement of vanilloid-like receptors in the effects of anandamide on motor behavior and nigrostriatal dopaminergic activity: in vivo and in vitro evidence. Brain Res. 1007 (2004) 152-159
10. De Petrocellis L., Bisogno T., Davis J.B., Pertwee R.G., and Di Marzo V. Overlap between the ligand recognition properties of the anandamide transporter and the VR1 vanilloid receptor: inhibitors of anandamide uptake with negligible capsaicin-like activity. FEBS Letters 483 (2000) 52-56
11. Di Marzo V. Targeting the endocannabinoid system: to enhance or reduce?. Nat. Rev. Drug Discov. 7 (2008) 438-455
12. Di Marzo V., and Cristino L. Why endocannabinoids are not all alike. Nat. Neurosci. 11 (2008) 124-126
13. Di Marzo V., Hill M.P., Bisogno T., Crossman A.R., and Brotchie J.M. Enhanced levels of endogenous cannabinoids in the globus pallidus are associated with a reduction in movement in an animal model of Parkinson's disease. FASEB J. 14 (2000) 1432-1438
14. Di Marzo V., Lastres-Becker I., Bisogno T., De Petrocellis L., Milone A., Davis J.B., and Fernandez-Ruiz J.J. Hypolocomotor effects in rats of capsaicin and two long chain capsaicin homologues. Eur. J. Pharmacol. 420 (2001) 123-131
15. Egertova M., Cravatt B.F., and Elphick M.R. Comparative analysis of fatty acid amide hydrolase and cb(1) cannabinoid receptor expression in the mouse brain: evidence of a widespread role for fatty acid amide hydrolase in regulation of endocannabinoid signaling. Neuroscience 119 (2003) 481-496
16. File S.E. Usefulness of animal models with newer anxiolytics. Clinic Neuropharmacol. 15 (1992) 525A-526A
17. Fu M., Xie Z., and Zuo H. TRPV1: a potential target for antiepileptogenesis. Med. Hypotheses 73 (2009) 100-102
18. Giuffrida A., Parsons L.H., Kerr T.M., Rodríguez de Fonseca F., Navarro M., and Piomelli D. Dopamine activation of endogenous cannabinoid signaling in dorsal striatum. Nat. Neurosci. 2 (1999) 358-363
19. Gubellini P., Picconi B., Bari M., Battista N., Calabresi P., Centonze D., Bernardi G., Finazzi-Agrò A., and Maccarrone M. Experimental parkinsonism alters endocannabinoid degradation: implications for striatal glutamatergic transmission. J. Neurosci. 22 (2002) 6900-6907
20. Joseph J.D., Wang Y.M., Miles P.R., Budygin E.A., Picetti R., Gainetdinov R.R., Caron M.G., and Wightman R.M. Dopamine autoreceptor regulation of release and uptake in mouse brain slices in the absence of D(3) receptors. Neuroscience 112 (2002) 39-49
21. Karanian D.A., Karim S.L., Wood J.T., Williams J.S., Lin S., Makriyannis A., and Bahr B.A. Endocannabinoid enhancement protects against kainic acid-induced seizures and associated brain damage. J. Pharmacol. Exp. Ther. 322 (2007) 1059-1066
22. Katona I., Sperlagh B., Sik A., Kafalvi A., Vizi E.S., Mackie K., and Freund T.F. Presynaptically located CB1 cannabinoid receptors regulate GABA release from axon terminals of specific hippocampal interneurons. J. Neurosci. 19 (1999) 4544-4558
23. Koeltzow T.E., Xu M., Cooper D.C., Hu X.T., Tonegawa S., Wolf M.E., and White F.J. Alterations in dopamine release but not dopamine autoreceptor function in dopamine D3 receptor mutant mice. J. Neurosci. 18 (1998) 2231-2238
24. Krahl S.E., Senanayake S.S., and Handforth A. Destruction of peripheral C-fibers does not alter subsequent vagus nerve stimulation-induced seizure suppression in rats. Epilepsia 42 (2001) 586-589
25. Lafenêtre P., Chaouloff F., and Marsicano G. The endocannabinoid system in the processing of anxiety and fear and how CB1 receptors may modulate fear extinction. Pharmacol. Res. 56 (2007) 367-381
26. Laviolette S.R., and Grace A.A. The roles of cannabinoid and dopamine receptor systems in neural emotional learning circuits: implications for schizophrenia and addiction. Cell. Mol. Life Sci. 63 (2006) 1597-1613
27. Lee J., Di Marzo V., and Brotchie J.M. A role for vanilloid receptor 1 (TRPV1) and endocannabinnoid signalling in the regulation of spontaneous and L-DOPA induced locomotion in normal and reserpine-treated rats. Neuropharmacology 51 (2006) 557-565
28. Leggio G.M., Mazzola C., Micale V., Consoli D., Ignoto T., and Drago F. D3 dopamine receptor knockout mice: behavioral alteration in experimental models of anxiety. Eur. Neuropsychopharmacol. 15 (2005) S41
29. Leggio G.M., Micale V., and Drago F. Increased sensitivity to antidepressants of D(3) dopamine receptor-deficient mice in the forced swim test (FST). Eur. Neuropsychopharmacol. 18 (2008) 271-277
30. Levant B. The D3 dopamine receptor: neurobiology and potential clinical relevance. Pharmacol. Rev. 49 (1997) 231-252
31. Ludányi A., Eross L., Czirják S., Vajda J., Halász P., Watanabe M., Palkovits M., Maglóczky Z., Freund T.F., and Katona I. Downregulation of the CB1 cannabinoid receptor and related molecular elements of the endocannabinoid system in epileptic human hippocampus. J. Neurosci. 28 (2008) 2976-2990
32. Maccarrone M., Rossi S., Bari M., De Chiara V., Fezza F., Musella A., Gasperi V., Prosperetti C., Bernardi G., Finazzi-Agrò A., Cravatt B.F., and Centonze D. Anandamide inhibits metabolism and physiological actions of 2-arachidonoylglycerol in the striatum. Nat. Neurosci. 11 (2008) 152-159
33. Maione S., Bisogno T., de Novellis V., Palazzo E., Cristino L., Valenti M., Petrosino S., Guglielmotti V., Rossi F., and Di Marzo V. Elevation of endocannabinoid levels in the ventrolateral periaqueductal grey through inhibition of fatty acid amide hydrolase affects descending nociceptive pathways via both cannabinoid receptor type 1 and transient receptor potential vanilloid type-1 receptors. J. Pharmacol. Exp. Ther. 316 (2006) 969-982
34. Maione S., De Petrocellis L., de Novellis V., Moriello A.S., Petrosino S., Palazzo E., Rossi F.S., Woodward D.F., and Di Marzo V. Analgesic actions of N-arachidonoyl-serotonin, a fatty acid amide hydrolase inhibitor with antagonistic activity at vanilloid TRPV1 receptors. Br. J. Pharmacol. 150 (2007) 766-781
35. Mangieri R.A., and Piomelli D. Enhancement of endocannabinoid signaling and the pharmacotherapy of depression. Pharmacol. Res. 56 (2007) 360-366
36. Marinelli S., Pascucci T., Bernardi G., Puglisi-Allegra S., and Mercuri N.B. Activation of TRPV1 in the VTA excites dopaminergic neurons and increases chemical- and noxious-induced dopamine release in the nucleus accumbens. Neuropsychopharmacology 30 (2005) 864-870
37. Marinelli S., Di Marzo V., Florenzano F., Fezza F., Viscomi M.T., van der Stelt M., Bernardi G., Molinari M., Maccarrone M., and Mercuri N.B. N-arachidonoyl-dopamine tunes synaptic transmission onto dopaminergic neurons by activating both cannabinoid and vanilloid receptors. Neuropsychopharmacology 32 (2007) 298-308
38. Marsch R., Foeller E., Rammes G., Bunck M., Kössl M., Holsboer F., Zieglgänsberger W., Landgraf R., Lutz B., and Wotjak C.T. Reduced anxiety, conditioned fear, and hippocampal long-term potentiation in transient receptor potential vanilloid type 1 receptor-deficient mice. J. Neurosci. 27 (2007) 832-839
39. Marsicano G., Goodenough S., Monory K., Hermann H., Eder M., Cannich A., Azad S.C., Cascio M.G., Gutiérrez S.O., van der Stelt M., López-Rodriguez M.L., Casanova E., Schütz G., Zieglgänsberger W., Di Marzo V., Behl C., and Lutz B. CB1 cannabinoid receptors and on-demand defense against excitotoxicity. Science 302 (2003) 84-88
40. Micale V., Mazzola C., and Drago F. Endocannabinoids and neurodegenerative diseases. Pharmacol. Res. 56 (2007) 382-392
41. Micale V., Tamburella A., Leggio G.M., Mazzola C., Li Volsi V., and Drago F. Behavioral effects of saredutant, a tachykinin NK2 receptor antagonist, in experimental models of mood disorders under basal and stress-related conditions. Pharmacol. Biochem. Behav. 90 (2008) 463-469
42. Micale V., Cristino L., Tamburella A., Petrosino S., Leggio G.M., Drago F., and Di Marzo V. Anxiolytic effects in mice of a dual blocker of fatty acid amide hydrolase and transient receptor potential vanilloid type-1 channels. Neuropsychopharmacology 34 (2009) 593-606
43. Monory K., Massa F., Egertová M., Eder M., Blaudzun H., Westenbroek R., Kelsch W., Jacob W., Marsch R., Ekker M., Long J., Rubenstein J.L., Goebbels S., Nave K.A., During M., Klugmann M., Wölfel B., Dodt H.U., Zieglgänsberger W., Wotjak C.T., Mackie K., Elphick M.R., Marsicano G., and Lutz B. The endocannabinoid system controls key epileptogenic circuits in the hippocampus. Neuron 51 (2006) 455-466
44. Morgese M.G., Cassano T., Cuomo V., and Giuffrida A. Anti-dyskinetic effects of cannabinoids in a rat model of Parkinson's disease: role of CB(1) and TRPV1 receptors. Exp. Neurol. 208 (2007) 110-119
45. Naderi N., Aziz Ahari F., Shafaghi B., Najarkolaei A.H., and Motamedi F. Evaluation of interactions between cannabinoid compounds and diazepam in electroshock-induced seizure model in mice. J. Neural Transm. 115 (2008) 1501-1511
46. Olsen R.W. The GABA postsynaptic membrane receptor-ionophore complex. Site of action of convulsant and anticonvulsant drugs. Mol. Cell. Biochem. 39 (1981) 261-279
47. Patel S., Rademacher D.J., and Hillard C.J. Differential regulation of the endocannabinoids anandamide and 2-arachidonylglycerol within the limbic forebrain by dopamine receptor activity. J. Pharmacol. Exp. Ther. 306 (2003) 880-888
48. Pellow S., Chopin P., and File S.E. Are the anxiogenic effects of yohimbine mediated by its action at benzodiazepine receptors?. Neurosci. Lett. 55 (1985) 5-9
49. Pertwee R.G. The therapeutic potential of drugs that target cannabinoid receptors or modulate the tissue levels or actions of endocannabinoids. AAPS J. 7 (2005) E625-E654
50. Piomelli D. The molecular logic of endocannabinoid signalling. Nat. Rev. Neurosci. 4 (2003) 873-884
51. Pritchard L.M., Logue A.D., Hayes S., Welge J.A., Xu M., Zhang J., Berger S.P., and Richtand N.M. 7-OH-DPAT and PD 128907 selectively activate the D3 dopamine receptor in a novel environment. Neuropsychopharmacology 28 (2003) 100-107
52. Rubino T., Realini N., Castiglioni C., Guidali C., Vigano D., Marras E., Petrosino S., Perletti G., Maccarrone M., Di Marzo V., and Parolaio D. Role in anxiety behavior of the endocannabinoid system in the prefrontal cortex. Cereb. Cortex 18 (2008) 1292-1301
53. Sokoloff P., Giros B., Martres M.P., Bouthenet M.L., and Schwartz J.C. Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics. Nature 347 (1990) 146-151
54. Sokoloff P., Diaz J., Le Foll B., Guillin O., Leriche L., Bezard E., and Gross C. The dopamine D3 receptor: a therapeutic target for the treatment of neuropsychiatric disorders. CNS Neurol. Disord. Drug Targets 5 (2006) 25-43
55. Starowicz K., Maione S., Cristino L., Palazzo E., Marabese I., Rossi F., de Novellis V., and Di Marzo V. Tonic endovanilloid facilitation of glutamate release in brainstem descending antinociceptive pathways. J. Neurosci. 27 (2007) 13739-13749
56. Starowicz K., Cristino L., and Di Marzo V. TRPV1 receptors in the central nervous system: potential for previously unforeseen therapeutic applications. Curr. Pharm. Des. 14 (2008) 42-54
57. Steiner H., Fuchs S., and Accili D. D3 dopamine receptor-deficient mouse: evidence for reduced anxiety. Physiol. Behav. 63 (1997) 137-141
58. Tsou K., Brown S., Sañudo-Peña M.C., Mackie K., and Walker J.M. Immunohistochemical distribution of cannabinoid CB1 receptors in the rat central nervous system. Neuroscience 83 (1998) 393-411
59. Tzavara E.T., Li D.L., Moutsimilli L., Bisogno T., Di Marzo V., Phebus L.A., Nomikos G.G., and Giros B. Endocannabinoids activate transient receptor potential vanilloid 1 receptors to reduce hyperdopaminergia-related hyperactivity: therapeutic implications. Biol. Psychiatry 59 (2006) 508-515
60. van der Stelt M., and Di Marzo V. The endocannabinoid system in the basal ganglia and in the mesolimbic reward system: implications for neurological and psychiatric disorders. Eur. J. Pharmacol. 480 (2003) 133-150
61. Veldhuis W.B., van der Stelt M., Wadman M.W., van Zadelhoff G., Maccarrone M., Fezza F., Veldink G.A., Vliegenthart J.F., Bär P.R., Nicolay K., and Di Marzo V. Neuroprotection by the endogenous cannabinoid anandamide and arvanil against in vivo excitotoxicity in the rat: role of vanilloid receptors and lipoxygenases. J. Neurosci. 23 (2003) 4127-4133